SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Supriya Lifescience - Quaterly Results

07 Nov 2023 Evaluate
The company witnessed a 24.89% growth in the revenue at Rs. 1400.95 millions for the quarter ended September 2023 as compared to Rs. 1121.72 millions during the year-ago period.A good growth in profit of 41.64% reported to Rs. 238.84  millions over Rs. 168.62 millions of corresponding previous quarter.The company reported a good operating profit of 342.19 millions compared to 311.67 millions of corresponding previous quarter.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202309 202209 % Var 202309 202209 % Var 202303 202203 % Var
Sales 1400.95 1121.72 24.89 2721.16 2135.27 27.44 4609.38 5300.49 -13.04
Other Income 24.67 26.05 -5.30 53.85 49.62 8.52 94.89 75.77 25.23
PBIDT 342.19 311.67 9.79 816.28 647.70 26.03 1383.87 2215.62 -37.54
Interest 4.60 7.75 -40.65 12.76 13.56 -5.90 30.84 41.98 -26.54
PBDT 337.59 303.92 11.08 803.52 634.14 26.71 1353.03 2173.64 -37.75
Depreciation 39.81 29.73 33.91 79.36 58.58 35.47 118.15 101.18 16.77
PBT 297.78 274.19 8.60 724.16 575.56 25.82 1234.88 2072.46 -40.41
TAX 58.94 105.57 -44.17 200.20 154.44 29.63 336.30 554.35 -39.33
Deferred Tax -26.44 0.91 -3005.49 15.19 3.91 288.49 29.49 32.46 -9.15
PAT 238.84 168.62 41.64 523.96 421.12 24.42 898.58 1518.11 -40.81
Equity 160.97 160.97 0.00 160.97 160.97 0.00 160.97 160.97 0.00
PBIDTM(%) 24.43 27.79 -12.09 30.00 30.33 -1.11 30.02 41.80 -28.18

Supriya Lifescience Share Price

636.90 -1.05 (-0.16%)
13-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1652.00
Dr. Reddys Lab 1235.20
Cipla 1211.30
Zydus Lifesciences 923.10
Lupin 2312.35
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×